Molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae among the pediatric population in Qatar

Andres Perez-Lopez (✉ aperezlopez@sidra.org)
Sidra Medical and Research Center  https://orcid.org/0000-0002-2301-470X

Sathyavathi Sundararaju
Sidra Medical and Research Center

Hassan Al-Mana
Qatar University

Kin Ming Tsui
Sidra Medical and Research Center

Mohammad Hasan
Sidra Medical and Research Center

Patrick Tang
Sidra Medical and Research Center

Research article

Keywords: children, whole-genome sequencing, E. coli, K. pneumonia, extended-spectrum beta-lactamases; CTX-M-15

DOI: https://doi.org/10.21203/rs.3.rs-29509/v1

License: ☑ 锘 This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background:** Although extended-spectrum β-lactamase (ESBL)-producing *Enterobacteriaceae* are a public health problem in the Arabian Peninsula, data on the molecular characteristic of their antimicrobial resistance determinants in children is limited.

**Methods:** Whole-genome sequencing (WGS) was performed on ESBL-producing *E. coli* and *K. pneumoniae* isolates recovered from screening and clinical specimens from pediatric patients at Sidra Medicine in Doha from January to December 2018.

**Results:** WGS was performed on 327 ESBL producers: 255 *E. coli* and 72 *K. pneumoniae*. The most common sequence types (ST) were ST131 (16.5%), ST38 and ST10 (8.2 each%) in *E. coli* and ST307 (9.7%), ST45 and ST268 (6.9% each) in *K. pneumoniae*. CTX-M type ESBL were found in all but one isolate, with CTX-M-15 accounting for 87.8%. Co-carriage of OXA-1 alone or in combination with TEM-1B was associated with reduced susceptibility to amoxicillin/clavulanate (*P*=0.002 and *P*<0.0001) and piperacillin/tazobactam (*P*=0.02 and *P*=0.004). The most common plasmid-mediated quinolone resistance genes co-carried were *qnr A/B/E/S* (45.3%). Ninety percent of gentamicin non-susceptible isolates harboured genes encoding AAC(3) enzymes, mainly *aac(3)-Ila*. Only 2 of 57 isolates harbouring *aac(6′)-Ib-cr* were non-susceptible to amikacin. Eighty-five percent of isolates carried IncF plasmids.

**Conclusions:** Our data show that CTX-M is largely the most prevalent ESBL type in the pediatric population in Qatar with a predominance of CTX-M-15. Carbapenem-sparing options to treat ESBL infections are limited given the frequent co-production of OXA-1 and TEM-1B enzymes and co-resistance to antibiotic classes other than β-lactams.

Background

Over the last four decades, extended-spectrum β-lactamases (ESBLs) have presented a major challenge to treating infections caused by *Enterobacteriaceae* in healthcare and community settings [1–3]. Resistance to third- and fourth-generation cephalosporins mediated by ESBLs and the often associated co-resistance to other antibiotic classes such as fluoroquinolones, aminoglycosides and sulphonamides, has led to the increased use of carbapenems worldwide, which in turn is linked to increasing resistance to these agents [3–4]. Currently, the global epidemiology of ESBLs is dominated by CTX-M type enzymes, mainly due to the explosive dissemination of CTX-M-15 among *Escherichia coli* and *Klebsiella pneumoniae*. Nevertheless, regional variations in the prevalence, circulating enzyme types and sequence types (STs) among ESBL producers have been reported among different patient groups in different parts of the world [1–2].

Although the Arabian Peninsula is a region with one of the highest prevalence rates of ESBL-producing *Enterobacteriaceae* [5], the molecular epidemiology in children has never been studied using high-
resolution genomics. This study used whole-genome sequencing (WGS) to comprehensively characterize ESBL in *E. coli* and *K. pneumoniae* isolates recovered from screening and clinical specimens from pediatric patients at Sidra Medicine in Doha.

**Methods**

**Setting, isolates and screening protocol**

The study was conducted at Sidra Medicine, a new 400-bed tertiary care women’s and children's hospital in Doha that has been functioning at full capacity since January 2018. The hospital serves as a referral centre for the pediatric population of Qatar for all medical subspecialties, including oncology, neonatal intensive care and pediatric intensive care, and surgical specialties, including cardiac surgery and neurosurgery.

All non-duplicate ESBL-producing *E. coli* and *K. pneumoniae* isolates from clinical specimens as well as rectal swabs submitted for carbapenemase-producing organism (CPO) screening from children younger than 18 years of age with medical or surgical conditions that require an emergency or elective hospital admission were retrospectively studied for a one-year period, between January and December 2018.

As a part of the infection control surveillance program in our institution, a CPO questionnaire-based risk assessment is performed on emergency and elective admissions is performed. The questionnaire consists of three questions to identify previous colonization with multidrug-resistant organisms, and admission and history of invasive procedures in the last 12 months in other health care facilities within or outside of Qatar. Rectal swabs are collected from patients who answered affirmatively to any of the questions or from those who are unsure about the answer to any of the questions. In addition, patients admitted to the Neonatal Intensive Care Unit (NICU) and Pediatric Intensive Care Unit (PICU) are routinely screened for CPO carriage on admission and then once a week.

**Bacterial identification and antimicrobial susceptibility testing**

Screening rectal swabs were directly inoculated onto two selective chromogenic media (CHROMagar™ ESBL and CHROMagar™ mSuperCARBA, CHROMagar, France) to detect ESBL and carbapenemase producers, respectively. Colonies isolated from any of the screening media and *Enterobacteriaceae* isolated from clinical specimens, were identified using matrix-assisted laser-desorption ionization time-of-flight mass spectrometry (MALDI-TOF) (Bruker, Germany) and tested for antimicrobial susceptibility using the BD Phoenix™ automated identification and susceptibility testing system (Becton Dickinson, USA). Minimum inhibitory concentrations (MIC) and breakpoints were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) guidelines [6]. Isolates with intermediate susceptibility and resistant to each antibiotic tested were grouped in a single non-susceptible category. The CLSI susceptible-dose-
dependent category for cefepime was considered as intermediate for the purpose of this study. Non-susceptible isolates to any of the third-generation cephalosporins or cefepime were considered as potential ESBL producers.

**Whole-genome sequencing and bioinformatic analysis**

WGS was performed on all organisms with a susceptibility pattern consistent with ESBL production on the Illumina Miseq platform. Paired-end (PE) DNA libraries were constructed using Nextera XT (Illumina, San Diego, CA). The DNA was tagmented, amplified by index primers and purified with AMPure XP beads (Beckman Coulter, Brea, CA) to remove the smaller fragments. DNA libraries were then normalized, pooled and sequenced using the MiSeq platform generation 300 bp PE reads (MiSeq Reagent Kit V3). Raw reads were assessed by Fastqc (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and quality trimmed by Trim Galore (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) to eliminate adaptors and low quality sequences. Trimmed reads were assembled de novo using SPAdes v.3.9.0 [7], and smaller contigs (< 500 bp) were excluded. The assessment of all genome assemblies was performed using QUAST [8], contaminant reads were excluded after analysis by Kraken [9]. Sequence types (ST) and the genes encoding antimicrobial resistance for β-lactams, fluoroquinolones, aminoglycosides and trimethoprim-sulphamethoxazole (co-trimoxazole) were predicted based on the PubMLST typing schemes implemented in mlst (https://github.com/tseemann/mlst) and the ResFinder database [10] implemented in abricate (https://github.com/tseemann/abricate), respectively. The plasmids and incompatibility scheme were defined based on the PlasmidFinder database [11] and Kleborate [12]. The phylogroup and serotypes of *E. coli* were predicted using ClermonTyping [13] and ECTyper < https://github.com/phac-nml/ecoli_serotyping>. The relatedness of strains was inferred using Parsnp [14].

**Statistical analysis**

Associations were assessed by the chi-squared test with Yates’ correction for continuity, or Fisher’s exact test when an expected value was less than 5. In addition, the analysis of some variables was broken down into three different nursing units based on the CPO screening policy: PICU and NICU, where active surveillance of ESBL carriage was performed on a weekly basis; and General Pediatrics (GPED) included the remaining units in which ESBL colonisation were studied depending on the result of the risk assessment survey.

**Results**

A total of 327 ESBL producers were sequenced, 255 *E. coli* and 72 *K. pneumoniae* (Additional file 1). Of them, 203 *E. coli* (79.6%) and 55 *K. pneumoniae* (76.4%) were recovered from screening specimens. Sixty-nine strains were isolated from clinical specimens (*E. coli* 52 isolates; 25.5% and *K. pneumoniae* 17 isolates; 31.5%), including urine (36 isolates; 52.2%), peritoneal fluid (8 isolates; 11.6%), respiratory tract (7 isolates; 10.1%), blood stream (6 isolates; 8.7%), pus and wound (5 isolates; 7.2% each) and
cerebrospinal fluid (2 isolates; 2.9%). The proportion of clinical isolates in GPED, PICU and NICU were 27.6% (55 isolates), 8.9% (8 isolates) and 15.8% (6 isolates), respectively.

Eighty-eight different sequence types (STs) were detected in *E. coli*, whereas 36 STs were found in *K. pneumoniae*. The 5 most prevalent STs in *E. coli* were ST131 (42 isolates; 16.5%) followed by ST38 and ST10 (21 isolates; 8.2% each), ST1193 (10 isolates; 3.9%) and ST73 (8 isolates; 3.1%). All ST131 isolates belonged to phylogroup B2. O25:H4 accounted for 23 ST131 clones (54.8%). The 3 most common STs among *K. pneumoniae* isolates were ST307 (7 isolates; 9.7%) followed by ST45 and ST268 (5 isolates; 6.9% each) (Additional file 1 and Additional file 2).

Eighty percent of NICU isolates, including all *K. pneumoniae* isolates, were detected during hospital stay. Carriage acquisition rate and infection acquisition rate in NICU during hospitalisation for the study period were 3.28/1000 patient-days and 0.82/1000 patient-days. Twenty-nine percent of PICU isolates were detected during hospitalization. Carriage acquisition rate and infection acquisition rate in PICU were 5.82/1000 patient-days and 0.76/1000 patient-days. There were no outbreaks detected in these units during the study.

Overall, non-susceptibility rates among ESBL-producing *E. coli* and *K. pneumoniae* isolates were 99.2% and 98.6% for ceftriaxone, 60.2% and 87.3% for ceftazidime, 68.8% and 73.2% for cefepime, 46.5% and 70.8% for amoxicillin/clavulanate, 12.5% and 31% for piperacillin/tazobactam, 5.1% and 9.9% for ertapenem, 3.1% and 8.5% for meropenem, 18.4% and 29.6% for gentamicin, 0.8% and 4.2% for amikacin, 41.4% and 40.8% for ciprofloxacin, 66% and 76.1% for co-trimoxazole, and 7.8% and 60.6% for nitrofurantoin. There were no significant differences in non-susceptibility rates between clinical and screening isolates by nursing unit. Of the total 69 bacterial isolates recovered from clinical specimens, 42% (29 isolates) and 20.3% (14 isolates) were non-susceptible to amoxicillin/clavulanate and piperacillin/tazobactam. By contrast, non-susceptibility among clinical isolates to ertapenem and amikacin was 3% (2 isolates) and 1.5% (1 isolate). All 29 urinary isolates of *E. coli* were susceptible to nitrofurantoin.

WGS revealed that all 327 isolates except one carried CTX-M genes. The predominant gene detected was *bla*<sub>CTX-M-15</sub> in 287 isolates (87.8%), followed by *bla*<sub>CTX-M-14</sub> and *bla*<sub>SHV-106</sub> in 9 isolates each (2.8%). ESBL-producing *E. coli* and ESBL-producing *K. pneumoniae* were isolated simultaneously from 17 samples with *bla*<sub>CTX-M-15</sub> detected in both species in 16 of those samples.

Sixty-seven percent of isolates co-produced one or more β-lactamases. The most common genes were *bla*<sub>TEM-1B</sub> and *bla*<sub>OXA-1</sub> in 134 (41%) and 64 (19.6%) isolates, respectively. CTX-M-15 was present in all isolates carrying *bla*<sub>OXA-1</sub> (Table 1).
We further assessed the association between co-production of TEM-1B and OXA-1 enzymes and non-susceptibility to amoxicillin/clavulanate and piperacillin/tazobactam, after excluding the confounding influence of other β-lactamases active against β-lactamase inhibitors, namely plasmid-mediated AmpC β-

|                      | GPED (No=199) | NICU (No=38) | PICU (No=90) |
|----------------------|---------------|--------------|--------------|
|                      | E. coli (No=169) | K. pneumoniae (No=30) | E. coli (No=19) | K. pneumoniae (No=19) | E. coli (No=67) | K. pneumoniae (No=23) |
| **ESBL genes**       |               |              |              |                       |               |                      |
| bladCTXM-15          | 143 (84.1)    | 30 (100)     | 19 (100)     | 18 (94.7)              | 56 (83.5)     | 21 (91.3)            |
| bladCTXM-14          | 8 (4.7)       | -            | -            | -                      | -             | 1 (4.3)              |
| bladTEM-101          | 0             | 6 (20)       | 2 (10.5)     | -                      | -             | 1 (4.3)              |
| bladTEM-102          | 5 (3)         | -            | -            | -                      | 3 (4.5)       | -                    |
| bladTEM-101          | 5 (3)         | -            | -            | -                      | 3 (4.3)       | -                    |
| bladTEM-102          | 5 (3)         | -            | -            | -                      | 2 (3)         | -                    |
| bladTEM-103          | 2 (1.2)       | -            | -            | 2 (10.5)               | -             | 2 (8.6)              |
| bladTEM-104          | 1 (0.6)       | -            | -            | -                      | 2 (3)         | 1 (4.3)              |
| **Other βL genes**   |               |              |              |                       |               |                      |
| bladTEM-105          | 61 (36.1)     | 16 (53.3)    | 14 (73.7)    | 12 (63.2)              | 24 (35.8)     | 7 (34.8)             |
| bladCTMX8            | 23 (13.6)     | 17 (56.7)    | 5 (26.3)     | 8 (42.1)               | 7 (10.4)      | 4 (17.4)             |
| bladTEM-106          | 3 (3)         | -            | -            | 2 (10.5)               | 1 (4.3)       | -                    |
| bladTEM-107          | 6 (3.6)       | 2 (6.7)      | -            | -                      | 1 (4.3)       | -                    |
| bladTEM-108          | 6 (3.6)       | -            | -            | -                      | 1 (4.3)       | -                    |
| bladTEM-109          | 4 (2.4)       | 1 (3.3)      | -            | -                      | 1 (1.5)       | -                    |
| bladTEM-110          | 2 (1.2)       | -            | -            | -                      | 3 (4.5)       | -                    |
| **PMQR-G**           |               |              |              |                       |               |                      |
| aac(6’)-Ib-cr       | 21 (12.4)     | 14 (46.7)    | 3 (15.8)     | 7 (36.7)               | 8 (11.9)      | 4 (17.4)             |
| qacA                 | -             | 26 (86.7)    | -            | 18 (94.7)              | 1 (1.5)       | 23 (100)             |
| qepA                 | -             | -            | 2 (10.5)     | -                      | -             | -                    |
| qnrA/B/E/S           | 64 (37.9)     | 21 (70)      | 7 (36.8)     | 11 (57.9)              | 28 (41.8)     | 17 (73.9)            |
| **AME-G**            |               |              |              |                       |               |                      |
| aac(3)-Ib*           | 28 (16.6)     | 11 (36.7)    | 5 (26.2)     | 8 (42.1)               | 11 (16.4)     | 1 (4.3)              |
| aadA1                | 18 (10.7)     | 4 (13.3)     | -            | 2 (10.5)               | 10 (14.9)     | 1 (4.3)              |
| aadA2                | 6 (3.6)       | 6 (20)       | 6 (31.6)     | 2 (10.5)               | 5 (7.7)       | 5 (21.7)             |
| aadA3                | 11 (6.6)      | 2 (6.7)      | 1 (3.3)      | -                      | 22 (32.3)     | 1 (4.3)              |
| aph(3’)-Ia           | 13 (7.7)      | 4 (13.3)     | -            | 2 (10.5)               | 2 (3)         | 4 (17.4)             |
| aph(3’)-Ib           | 72 (42.6)     | 21 (70)      | 6 (31.6)     | 14 (73.7)              | 32 (47.8)     | 15 (65.2)            |
| aph(6’)-Ib          | 69 (40.8)     | 21 (70)      | 6 (31.6)     | 14 (73.7)              | 33 (49.3)     | 16 (63.2)            |
| **SXT-RG**           |               |              |              |                       |               |                      |
| dfrA/B               | 114 (67.4)    | 25 (83.3)    | 13 (69.4)    | 12 (63.2)              | 45 (68.7)     | 14 (60.8)            |
| sulI-3               | 112 (66.3)    | 24 (80)      | 14 (73.7)    | 15 (78.9)              | 46 (66.7)     | 14 (60.9)            |

PMQR-G: Plasmid-mediated quinolone resistance genes; AME-G: Aminoglycoside modifying enzyme genes; SXT-RG: co-trimoxazole resistance genes.

*Comprised aac(3)-Ib and aac(3)-IId, aac(3)-Iva and aac(3)-Via.

We further assessed the association between co-production of TEM-1B and OXA-1 enzymes and non-susceptibility to amoxicillin/clavulanate and piperacillin/tazobactam, after excluding the confounding influence of other β-lactamases active against β-lactamase inhibitors, namely plasmid-mediated AmpC β-
lactamases, (DHA-1, CMY 1/2/135), inhibitor-resistant TEM mutants (TEM 33/35) and carbapenemases (OXA-48-type and NDM-type). Non-susceptibility to amoxicillin/clavulanate was observed in 53.9% of isolates (48/89) carrying \( \text{bla}_{\text{TEM-1B}} \) alone \( (P < 0.001) \) and 75% (15/20) carrying \( \text{bla}_{\text{OXA-1}} \) alone \( (P = 0.002) \), whereas non-susceptibility to piperacillin/tazobactam was observed in 5.6% of isolates (5/89) carrying \( \text{bla}_{\text{TEM-1B}} \) alone \( (P = 0.5) \) and 25% (5/20) carrying \( \text{bla}_{\text{OXA-1}} \) alone \( (P = 0.02) \). Thirty-one of the 32 isolates (96.8%) carrying both enzymes simultaneously were non-susceptible to amoxicillin/clavulanate \( (P < 0.0001) \), whereas 15 (46.9%) of them were non-susceptible to piperacillin/tazobactam \( (P = 0.004) \).

At least one plasmid-mediated quinolone resistance (PMQR) gene was detected in 199 isolates (60.9%). PMQR genes found were \( \text{qnr A/B/E/S} \) in 148 isolates (45.3%), \( \text{oqxAB} \) in 68 isolates (20.8%), \( \text{aac(6')-Ib-cr} \) in 57 isolates (17.4%) and \( \text{qepA} \) in 2 isolates (0.6%). \( \text{oqxAB} \) were mostly detected in \( K. \text{pneumoniae} \) (67/68 isolates; 98.5%). Fifteen different aminoglycoside modifying enzymes genes were detected. Ninety percent of isolates non-susceptible to gentamicin carried genes encoding AAC(3) enzymes (61/68 isolates). Conversely, only 2 (3.5%) of the 57 isolates harbouring \( \text{aac(6')-Ib-cr} \) were non-susceptible to amikacin. All 4 isolates with high-level resistance to amikacin carried 16S rRNA methylase genes \( (2 \text{ rmtB} \) and \( 2 \text{ armA}) \). The simultaneous carriage of \( \text{bla}_{\text{OXA-1}}, \text{aac(6')-Ib-cr} \) and \( \text{aac(3)-II} \) was strongly associated \( (P < 0.0001) \). Eighty-nine percent of the isolates harbouring the \( \text{dfrA17} \) gene also carried the \( \text{aadA5} \) gene while all isolates harbouring \( \text{dfrA12} \) carried \( \text{aadA2} \) genes (Table 1).

Narrow host-range IncF plasmids were present in 278 isolates (85%). FIB was the most common F replicon found in 243 isolates (74.3%) followed by FII in 162 isolates (49.5%) and FIA 99 isolates (30.3%). In addition, 10 more incompatibility group plasmids were detected, mostly as a part of multiple combinations with F replicons. The 3 most prevalent were: \( \text{IncI1} \) (62 isolates; 19%), \( \text{IncX} \) (27 isolates; 8.3%) and \( \text{IncB/O/K/Z} \) (25 isolates; 7.6%). On the other hand, 189 isolates (57.8%) contained col-type plasmids. RNAI (119 isolates, 36.4%), col156 (88 isolates; 26.9%) and MG828 (46 isolates; 14%) were the most common representatives within this group. Plasmid location of \( \text{bla}_{\text{CTX-M}} \) genes could be determined in 21 isolates (Table 2). Twenty-one isolates (6.4%) did not have any plasmid detected.
Discussion

Our data show that CTX-M are largely the most common ESBL type in the pediatric population in Qatar with CTX-M-15 as the main driving force. Our study also points out that narrow host range plasmids, mainly those belonging to the IncF family, are likely the main vehicle for the dissemination of \( \text{bla}_{\text{CTX-M-15}} \) along with other resistance genes such as \( \text{bla}_{\text{OXA-1}} \), \( \text{aac(6')-Ib-cr} \) and \( \text{aac(3)-II} \) among a great diversity of genotypes within \( E. coli \) and \( K. pneumoniae \) [15–16]. These findings are not surprising taking into account that expatriates comprise around 87% of the Qatar’s population with citizens from the Indian subcontinent representing almost 50% [17]. Therefore, it is reasonable to hypothesize that our data mainly reflect an epidemiological trend in the general population, which is likely shaped by a high rate of community carriage among residents from countries such as India, Nepal and Bangladesh, where rates of CTX-M-15 among faecal isolates from healthy individuals and clinical isolates have been reported above 90% [18–22]. In contrast, our NICU had a variety genotypes of both species without subsequent significant cross-transmission, suggesting a sporadic colonisation/infection within a group that is at particular high risk for ESBL acquisition [23].

Sequence analysis revealed that the management of ESBL infections in our paediatric population is challenging, particularly concerning carbapenem-sparing options. The effect of clavulanic acid and
tazobactam in inhibiting CTX-M enzymes is often counteracted in our isolates by the co-production of TEM-1B and OXA-1 [24], and to a lesser extent by other enzymes such as plasmid-mediated AmpC and carbapenemases. For example, amoxicillin/clavulanate does not seem to be a reliable agent for the treatment of uncomplicated ESBL lower urinary tract infections (UTI). Fortunately, nitrofurantoin remains a good option in this scenario, especially in cases caused by *E. coli*. On the other hand, although TEM-1B seems to have a poor inhibitory effect against tazobactam, the common co-production of OXA-1 alone or accompanied by TEM-1B, makes piperacillin/tazobactam an unreliable agent for the empirical or definitive treatment of systemic ESBL infections in our context, irrespective of the unresolved controversy concerning the usefulness of this agent in high-inoculum infections [4, 25–26]. Although ertapenem seems to be an appealing option, the non-susceptible rate in the whole collection of isolates was not negligible. It should be noted that 3 out of 20 non-susceptible isolates to ertapenem carrying *bla*<sub>CTX-M-15</sub> lacked genes encoding carbapenemases or AmpC β-lactamases, suggesting that ertapenem can also be a substrate for CTX-M-15 when its penetration through the outer membrane is reduced due to porin deficiencies [27]. Particularly noteworthy was high proportion of isolates susceptible to amikacin despite the presence *aac(6')-Ib-cr* genes in 17% of strains. Although monotherapy with amikacin has been proposed to treat febrile UTI in children in regions with low resistance rates among ESBL producers [23, 28–29], it should be kept in mind that it is not uncommon to find susceptible isolates according to the CLSI breakpoints (MIC ≤ 16 mg/L) harbouring *aac(6')-Ib-cr* with MICs between 4 and 8 mg/L [2430]. Therefore, it might be speculated that the ratio C<sub>max</sub>/MIC, the main pharmacodynamic parameter that predicts bacterial killing and prevent selection of resistance in aminoglycosides [31–32], could be often compromised when *aac(6')-Ib-cr* is carried. The high ciprofloxacin non-susceptibility rate was also noticeable, given that quinolones are rarely prescribed in our pediatric institution. Although *oqxAB* genes are mainly chromosomally located in *K. pneumoniae* [33], the high proportion of PMQR determinants in our isolates suggests that transmission of these genes among commensal intestinal flora through the plasmid types reported here, may be facilitating the selection and spread of resistant mutants in the community [34–35]. Finally, it was not surprising to find a high co-resistance rate to co-trimoxazole, which renders this combination ineffective at least as empirical therapy. Interestingly, the strong association between *dfrA17* and *aadA5* genes and between *dfrA12* and *aadA2* genes suggests that class 1 integrons were not uncommon in our isolates. Class 1 integrons containing these gene cassette combinations are often located in IncF plasmids along with resistance genes such as *bla*<sub>CTX-M-15</sub>, *bla*<sub>OXA-1</sub> and *aac(6')-Ib-cr* [36–37].

Our study has several limitations. Since MICs were determined by the Phoenix automated system, which does not always provide an exact value within the susceptibility range, low-level resistance conferred by certain genes could not be assessed when MICs did not exceed susceptible breakpoints, for instance, low-level amikacin resistance in isolates carrying *aac(6')-lb-cr* or low-level piperacillin/tazobactam resistance in the presence of OXA-1 enzyme [24, 30]. Moreover, the activity of other potential useful agents available in Qatar, particularly ceftazidime-avibactam, ceftolozane-tazobactam and fosfomycin, could not be assessed because susceptibility cards used in this study did not contain any of these antibiotics, although it could be assumed that ceftazidime-avibactam would have been effective against our isolates.
in the absence of co-production of NDM-type carbapenemases [4]. It should be also taken into account that the population studied mostly comprised children at risk for acquisition of multidrug-resistant bacteria, which may have biased the actual burden of some resistance determinants in our entire pediatric population. Finally, plasmid replicons were analysed using genome assemblies derived from short-read sequence data, which hindered reliable plasmid sequence reconstruction and elucidation of plasmid location of CTX-M genes in the majority of isolates. In fact, plasmid sequences were not detected by PlasmidFinder database in 21 isolates, which indicated the challenge on the inference of plasmids from fragmented, small-sized contigs but also by a potential chromosomal integration of \( \text{bla}_{\text{CTX-M}} \) genes, a phenomenon increasingly reported in clinical isolates [38–39].

**Conclusion**

In summary, our study showed that CTX-M enzymes are overwhelmingly prevalent in the pediatric population of Qatar with CTX-M-15 as the major driving force. High community carriage rates among a multinational population appears to be the main source for \( \text{bla}_{\text{CTX-M-15}} \) and other resistance genes, which are likely vehiculized and spread by epidemic plasmids. Our study also highlighted the promising value of NGS-based technologies to improve antibiotic prescribing practices by uncovering resistance mechanisms not detected by conventional phenotypic antimicrobial susceptibility testing. To the best of our knowledge, this is the first study characterizing ESBL in children using WGS in the Arabian Peninsula. Since the labour force from the Indian subcontinent also represents the largest group of foreign citizens in other Gulf States, we believe that our results could be extrapolated at least to the middle and eastern part of the region.

**Abbreviations**

ESBL  
extended-spectrum \( \beta \)-lactamase  
WGS  
whole-genome sequencing  
CPO  
carbapenemase-producing organism  
CLSI  
Clinical and Laboratory Standards Institute  
MIC  
minimum inhibitory concentration  
NICU  
Neonatal Intensive Care Unit  
PICU  
Pediatric Intensive Care Unit  
GPED
General Pediatrics
ST
sequence type
PMQR
plasmid-mediated quinolone resistance
UTI
urinary tract infection

Declarations

Ethics approval and consent to participate
Ethics approval for the study was obtained from the Institutional Review Board of Sidra Medicine.

Consent for publication
Not applicable

Availability of data and materials
Comprehensive molecular data for all isolates can be found in Additional file 1.

Competing interests
The authors have no conflicts of interest.

Funding
This study was funded by a Sidra Internal Research Funding grant (Project ID: SIRF_200040).

Authors' contributions
APL designed the study, analyzed data and drafted the manuscript; SS performed WGS, supported HAM in collecting isolates and performing antimicrobial susceptibility testing and revised the manuscript; HAM collected isolates, performed antimicrobial susceptibility testing on selected isolates, supported SS in performing WGS, carried out the statistical analysis and revised the manuscript; KMT performed the bioinformatic analysis and revised the manuscript; MH supervised WGS process and bioinformatic analysis and revised the manuscript; PT coordinated and supervised the project and substantially revised the manuscript. All authors read and approved the final version of the manuscript.
Acknowledgements

The authors would like to thank Will Hsiao and Jun Duan (BCCDC Public Health Laboratory, Vancouver, Canada) for technical assistance.

References

1. Bevan ER, Jones AM, Hawkey PM. Global epidemiology of CTX-M β-lactamases: temporal and geographical shifts in genotype. J Antimicrob Chemother. 2017;72:2145–55.
2. Woerther PL, Burdet C, Chachaty E, Andremont A. Trends in human fecal carriage of extended-spectrum β-lactamases in the community: Toward the globalization of CTX-M. Clin Microbiol Rev. 2013;26:744–58.
3. Peirano G, Pitout JDD. Extended-spectrum β-lactamase-producing Enterobacteriaceae: Update on molecular epidemiology and treatment options. Drugs. 2019;79:1529–41.
4. Tamma PD, Rodriguez-Banón J. The use of noncarbapenem β-lactams for the treatment of extended-spectrum β-Lactamase infections. Clin Infect Dis. 2015;4:972–80.
5. Morrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D. A review of ten years of the study for monitoring antimicrobial resistance trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel). 2013;6:1335–46.
6. Clinical and Laboratory Standards Institute. M100-S23. Performance standards for antimicrobial susceptibility testing: 28th informational supplement. Wayne: Clinical and Laboratory Standards Institute; 2018.
7. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19:455–77.
8. Gurevich A, Saveliev V, Vyahhi N, Tesler G, et al. QUAST: quality assessment tool for genome assemblies. Bioinformatics. 2013;29:1072–5.
9. Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact alignments. Genome Biol. 2014;15:R46.
10. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, et al. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother. 2012;67:2640–44.
11. Carattoli A, Zankari E, García-Fernández A, Voldby-Larsen M, Lund O, Villa L, et al. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. Antimicrob Agents Chemother. 2014;58:3895–903.
12. Lam MMC, Wick RR, Wyres KL, Gorrie CL, Judd LM, Jenney AWJ, et al. Genetic diversity, mobilisation and spread of the yersiniabactin-encoding mobile element ICEKp in Klebsiella pneumoniae populations. Microb Genom 2018; 4 (9).
13. Beghain J, Bridier-Nahmias A, Le Nagard H, Denamur E, Clermont O, et al. ClermontTyping: an easy-to-use and accurate in silico method for Escherichia genus strain phylotyping. Microb Genom 2018; 4 (7).

14. Treangen TJ, Ondov BD, Koren S, Phillippy AM, et al. The Harvest suite for rapid core-genome alignment and visualization of thousands of intraspecific microbial genomes. Genome Biol. 2014;15:524.

15. Carattolli A. Resistance plasmid families in Enterobacteriaceae. Antimicrob Agents Chemother. 2009;53:2227–38.

16. Mathers AJ, Peirano G, Pitout JD. The role of resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin Microbiol Rev. 2015;28:565–91.

17. De Bel-Air FD. Demography, Migration, and Labour Market in Qatar. No. 3/2017. Available at: http://gulfmigration.org/media/pubs/exno/GLMM_EN_2017_03.pdf, Accessed on October 07, 2019.

18. Ensor VM, Shahid, Evans T, Hawkey PM, et al. Occurrence, prevalence and genetic environment of CTX-M β-lactamases in Enterobacteriaceae from Indian hospitals. J Antimicrob Chemother. 2006;58:1260–3.

19. Chakraborty A, Adhikari P, Shenoy S, Saralaya V, et al. Clinical significance and phylogenetic background of extended spectrum β-lactamase producing Escherichia coli isolates from extra-intestinal infections. J Infect Public Health. 2015;8:248–53.

20. Sherchan JB, Hayakawa K, Miyoshi-Akiyama T, Ohmagari N, Kirikae T, Nagamatsu M, et al. Clinical epidemiology and molecular analysis of extended-spectrum-β-lactamase producing Escherichia coli in Nepal: Characteristics of sequence types 131 and 648. Antimicrob Agents Chemother. 2015;59:3424–32.

21. Islam MA, Amin MB, Roy S, Asaduzzaman M, Islam MR, Navab-Daneshmand T, et al. Fecal colonization with multidrug-resistant E. coli among healthy infants in rural Bangladesh. Front Microbiol. 2019;10:640.

22. Lina TT, Khajanchi BK, Azmi IJ, Islam MA, Mahmood B, Akter M, et al. Phenotypic and molecular characterization of extended-spectrum beta-lactamase-producing Escherichia coli in Bangladesh. PLoS One. 2014;9:e108735.

23. Bitsori M, Galanakis E. Treatment of urinary tract infections caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae. Pediatr Infect Dis J. 2019;38:e332–5.

24. Livermore DM, Day M, Cleary P, Hopkins KL, Toleman MA, Wareham DW, et al. OXA-1 β-lactamase and non-susceptibility to penicillin/β-lactamase inhibitor combinations among ESBL-producing Escherichia coli. J Antimicrob Chemother. 2019;74:326–33.

25. Harris PNA, Tambyah PA, Lye DC, Mo Y. Lee TH5, Yilmaz M, et al. Effect of piperacillin–tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA 2018; 320: 984–94.

26. Retamar P, López-Cerero L, Muniaín MA, Pascual A, Rodríguez-Baño J, ESBL-REIPI/GEIH, Group. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to
27. Nicolas-Chanoine MH, Mayer N, Guyot K, Dumont E, Pagès JM. Interplay between membrane permeability and enzymatic barrier leads to antibiotic-dependent resistance in *Klebsiella pneumoniae*. Front Microbiol. 2018;29:1422.

28. Amin O, Prestel C, Gonzalez MD, Lyon T, Shane A, Jaggi P, et al. Urinary tract infections with extended-spectrum-β-lactamase-producing bacteria. Case-control study. Pediatr Infect Dis J. 2020;39:211–16.

29. Polat M, Tapisiz A. Amikacin monotherapy for treatment of febrile urinary tract infection caused by extended-spectrum β-lactamase-producing *Escherichia coli* in children. Pediatr Infect Dis J. 2018;37:378–9.

30. Fernández-Martínez M, Miró E, Ortega A, Bou G, González-López JJ, Oliver A, et al. Molecular identification of aminoglycoside-modifying enzymes in clinical isolates of *Escherichia coli* resistant to amoxicillin/clavulanic acid isolated in Spain. Int J Antimicrob Agents. 2015;46:157–63.

31. Illamola SM, Sherwin CM, van Hasselt JGC. Clinical pharmacokinetics of amikacin in pediatric patients: A comprehensive review of population pharmacokinetic analyses. Clin Pharmacokinet. 2018;57:1217–28.

32. Smits A, De Cock RF, Allegaert K, Vanhaesebrouck S, Danhof M, Knibbe CA, et al. Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice. Antimicrob Agents Chemother. 2015;59:6344–51.

33. Yuan J, Xu X, Guo1 Q, Zhao X, Ye X, Guo Y, Wang M. Prevalence of the *oqxAB* gene complex in *Klebsiella pneumoniae* and *Escherichia coli* clinical isolates. J Antimicrob Chemother. 2012;67:1655–9.

34. Yassine I, Rafei R, Osman M, Mallat H, Dabboussi F, Hamze M. Plasmid-mediated quinolone resistance: Mechanisms, detection, and epidemiology in the Arab countries. Infect Genet Evol. 2019;4:104020.

35. Logan LK, Medernach RL, Rispens JR, Marshall SH, Hujer AM, Domitrovic TN, et al. Community origins and regional differences highlight risk of plasmid-mediated fluoroquinolone resistant Enterobacteriaceae infections in children. Pediatr Infect Dis J. 2019;38:595–99.

36. Oliveira-Pinto C, Diamantino C, Oliveira PL, Reis MP, Costa PS, Paiva MC, et al. Occurrence and characterization of class 1 integrons in *Escherichia coli* from healthy individuals and those with urinary infection. J Med Microbiol. 2017;66:577–83.

37. Burke L, Humphreys H, Fitzgerald-Hughes D. The molecular epidemiology of resistance in cefotaximase-producing *Escherichia coli* clinical isolates from Dublin, Ireland. Microbiob Drug Resist. 2016;22:552–8.

38. van Aartsen JJC, Moore CE, Parry CM, Turner P, Phot N, Mao S, et al. Epidemiology of paediatric gastrointestinal colonisation by extended spectrum cephalosporin-resistant *Escherichia coli* and *Klebsiella pneumoniae* isolates in north-west Cambodia. BMC Microbiol. 2019;19:59.
39. Rodríguez I, Thomas K, Van Essen A, Schink AK, Day M, Chattaway M, et al. Chromosomal location of blaCTX-M genes in clinical isolates of *Escherichia coli* from Germany, The Netherlands and the UK. Int J Antimicrob Agents. 2014;43:553–7.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1.Datasetforallisolates.xlsx
- Additionalfile2.PhylogenetictreemajorSTs.pptx